Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 3
2020 2
2021 7
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.
Zhang D, Liu X, Shen F, Zhao D, Shi Y, Zhang H, Liu J, Gao X, Chen M, Zhao J, Zhong W, Gao J, He M, Liu Y, Yang X, Qin J, Tang Y, Mu X, Gu Y, Zhang S, Chen X, Pang L, Meng Q, Guo Y, Zhang Y, Li W, Xing P, Cheng Y, Xin T, Li Q, Li Y, Chen J, Gao F, Jin B, Rossi A, Adachi H, Guerrera F, Husain H, Xu Y, Wang M. Zhang D, et al. Among authors: gu y. Transl Lung Cancer Res. 2023 Nov 30;12(11):2229-2244. doi: 10.21037/tlcr-23-577. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38090527 Free PMC article.
Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor.
Li Q, Sun T, Zhang H, Liu W, Xiao Y, Sun H, Yin W, Yao Y, Gu Y, Liu Y, Yi F, Wang Q, Yu J, Cao B, Liang L. Li Q, et al. Among authors: gu y. Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):137-146. doi: 10.3779/j.issn.1009-3419.2022.101.07. Zhongguo Fei Ai Za Zhi. 2022. PMID: 35340156 Free PMC article.
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.
Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q, Ding C, Ai B, Gu Y, Yao Y, Sun H, Guo H, Zhang C, Song X, Li J, Xu B, Han Z, Song M, Tang T, Chen P, Lu H, Shui Y, Lou G, Zhang D, Liu J, Liu X, Liu X, Gao X, Zhou Q, Chen M, Zhao J, Zhong W, Xu Y, Wang M. Shi Y, et al. Among authors: gu y. Thorac Cancer. 2022 Feb;13(3):412-422. doi: 10.1111/1759-7714.14274. Epub 2021 Dec 21. Thorac Cancer. 2022. PMID: 34935288 Free PMC article.
Blood T cell diversity associated with the prognosis of advanced non-small cell lung carcinoma treated with first-line pemetrexed based chemotherapy.
Qian L, Zhaohui Z, Yaping X, Zhentian L, Zhentao L, Qiqi W, Yangchun G, Yan'e L, Wencheng Y, Fumei Y, Yanhong Y, Baoshan C, Li L. Qian L, et al. Among authors: yangchun g. Thorac Cancer. 2021 Apr;12(7):997-1005. doi: 10.1111/1759-7714.13771. Epub 2021 Feb 24. Thorac Cancer. 2021. PMID: 33626215 Free PMC article.
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
Zou Z, Gu Y, Liang L, Hao X, Fan C, Xin T, Zhao S, Liu Z, Guo Y, Ma K, Li H, Zhang C, Shan L, Zhang Y, Dong G, Peng Y, Shen F, Song X, Christopoulos P, van der Wekken AJ, Okuda K, Ekman S, Xing P, Li J. Zou Z, et al. Among authors: gu y. Transl Lung Cancer Res. 2022 Dec;11(12):2495-2506. doi: 10.21037/tlcr-22-803. Transl Lung Cancer Res. 2022. PMID: 36636411 Free PMC article.
Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Zou Z, Hao X, Zhang C, Li H, Dong G, Peng Y, Ma K, Guo Y, Shan L, Zhang Y, Liang L, Gu Y, Xing P, Li J. Zou Z, et al. Among authors: gu y. Thorac Cancer. 2022 Jan;13(1):107-116. doi: 10.1111/1759-7714.14232. Epub 2021 Dec 1. Thorac Cancer. 2022. PMID: 34851035 Free PMC article.
20 results